Pharmacokinetics and metabolism of intravenous pirfenidone in sheep

被引:14
作者
Bruss, Michael L. [1 ]
Stanley, Scott D. [2 ]
Margolin, Solomon B. [3 ]
Giri, Shri N. [2 ,3 ]
机构
[1] Univ Calif Davis, Sch Vet Med, Dept Anat Physiol & Cell Biol, Davis, CA 95616 USA
[2] Univ Calif Davis, Dept Mol Biosci, Sch Vet Med, Davis, CA 95616 USA
[3] Marnac Inc, Dallas, TX USA
关键词
pirfenidone; sheep; pharmacokinetics; metabolism;
D O I
10.1002/bdd.595
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Pirfenidone, a promising antifibrotic agent, was administered intravenously to six female sheep at 30 mg/kg. Four sheep received C-14-pirfenidone simultaneously. Plasma and urine were obtained for assay of pirfenidone and its metabolites over two days, and tissues were obtained via necropsy. Samples were analysed for pirfenidone and metabolites using HPLC-MS and flow scintillation spectrometry. Plasma pirfenidone disappeared with first order kinetics with a clearance of 1.2 l/kg/h, half-life of 24 min, and distribution volume of 0.71 l/kg. After 48 h, the organs containing the largest quantity of C-14 were lungs, liver and intestinal wall. Tissues with the highest concentration of C-14 were lung, kidney, brain, liver, lymph node and adipose. Metabolites found in plasma and urine were hydroxypirfenidone (half-life of 44min) and carboxypirfenidone. Additional metabolites found in urine were hydroxypirfenidone glucuronide and acetoxypirfenidone. Approximately, 80% of the tracer eventually appeared in the urine, and approximately 50% of it was in the form of identifiable metabolites. Less than 1% of the dose appeared in the urine in the form of the parent drug. Quantitatively, most of the metabolites appeared in the urine within 2h. Thus, the drug is rapidly and completely metabolized. Copyright (C) 2008 John Wiley & Sons, Ltd.
引用
收藏
页码:119 / 126
页数:8
相关论文
共 18 条
  • [1] Phase I trial of pirfenidone in children with neurofibromatosis 1 and plexiform neurofibromas
    Babovic-Vuksanovic, Dusica
    Widemann, Brigitte C.
    Dombi, Eva
    Gillespie, Andrea
    Wolters, Pamela L.
    Toledo-Tamula, Mary Anne
    O'Neill, Brian P.
    Fox, Elizabeth
    MacDonald, Tobey
    Beck, Heather
    Packer, Roger J.
    [J]. PEDIATRIC NEUROLOGY, 2007, 36 (05) : 293 - 300
  • [2] INTERSPECIES PHARMACOKINETIC SCALING AND THE EVOLUTIONARY-COMPARATIVE PARADIGM
    BOXENBAUM, H
    [J]. DRUG METABOLISM REVIEWS, 1984, 15 (5-6) : 1071 - 1121
  • [3] BURSS ML, 2005, J VET PHARMACOL THER, V27, P361
  • [4] Pharmacokinetics and metabolism of a novel antifibrotic drug pirfenidone, in mice following intravenous administration
    Giri, SN
    Wang, QJ
    Xie, Y
    Lango, J
    Morin, D
    Margolin, SB
    Buckpitt, AR
    [J]. BIOPHARMACEUTICS & DRUG DISPOSITION, 2002, 23 (05) : 203 - 211
  • [5] Rodent models of the human acetylation polymorphism: Comparisons of recombinant acetyltransferases
    Hein, DW
    Doll, MA
    Fretland, AJ
    Gray, K
    Deitz, AC
    Feng, Y
    Jiang, W
    Rustan, TD
    Satran, SL
    Wilkie, TR
    [J]. MUTATION RESEARCH-FUNDAMENTAL AND MOLECULAR MECHANISMS OF MUTAGENESIS, 1997, 376 (1-2) : 101 - 106
  • [6] HIGA HH, 1989, J BIOL CHEM, V264, P19427
  • [7] Lung fibrosis is ameliorated by pirfenidone fed in diet after the second dose in a three-dose bleomycin-hamster model
    Iyer, SN
    Margolin, SB
    Hyde, DM
    Giri, SN
    [J]. EXPERIMENTAL LUNG RESEARCH, 1998, 24 (01) : 119 - 132
  • [8] IYER SN, 1995, J LAB CLIN MED, V125, P779
  • [9] Pirfenidone diminishes cyclophosphamide-induced lung fibrosis in mice
    Kehrer, JP
    Margolin, SB
    [J]. TOXICOLOGY LETTERS, 1997, 90 (2-3) : 125 - 132
  • [10] Reversal of cardiac and renal fibrosis by pirfenidone and spironolactone in streptozotocin-diabetic rats
    Miric, G
    Dallemagne, C
    Endre, Z
    Margolin, S
    Taylor, SM
    Brown, L
    [J]. BRITISH JOURNAL OF PHARMACOLOGY, 2001, 133 (05) : 687 - 694